Faron to Report Final Melanoma Survival Data from the MATINS Study at ESMO 2026
Final data in PD-1 refractory metastatic melanoma underpin the rationale for the ongoing BLAZE trial of bexmarilimab in combination with nivolumab TURKU, FI / ACCESS Newswire / October 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a …
Weiterlesen »